Bank of New York Mellon’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Bank of New York Mellon’s Portfolio ATXI Stock Details ATXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-688	Closed	-$36.5K	–	4400
2023 Q3	$36.5K	Sell	688 -18	-3%	-$1.27K	﹤0.01%	4195
2023 Q2	$62K	Sell	706 -6	-0.8%	-$494	﹤0.01%	4144
2023 Q1	$62.2K	Hold	712	–	–	﹤0.01%	4157
2022 Q4	$61.9K	Buy	+712	New	+$129K	﹤0.01%	4202
2021 Q2	–	Sell	-13	Closed	-$91K	–	4484
2021 Q1	$91K	Hold	13	–	–	﹤0.01%	4177
2020 Q4	$89K	Hold	13	–	–	﹤0.01%	4089
2020 Q3	$164K	Hold	13	–	–	﹤0.01%	3884
2020 Q2	$162K	Buy	+13	New	+$147K	﹤0.01%	3843

Other funds holding ATXI

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of New York Mellon's ATXI Position: Q4 2023 in Review

Bank of New York Mellon sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q4 2023, closing a stake of 688 shares — an estimated $36.5K sold.

Bank of New York Mellon first reported a position in ATXI in Q2 2020 and held it in 8 quarters. The position peaked at $164K in Q3 2020. 14 funds tracked by Wall St. Rank hold ATXI as of Q4 2023.

Bank of New York Mellon reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Bank of New York Mellon sold 688 Avenue Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $36.5K.
Bank of New York Mellon first reported a position in Avenue Therapeutics, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
Bank of New York Mellon's Avenue Therapeutics, Inc. Common Stock position peaked at $164K in Q3 2020.
14 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Bank of New York Mellon's 13F filing for Q4 2023, filed 29 Jan 2024.